Articolul precedent |
Articolul urmator |
1099 9 |
Ultima descărcare din IBN: 2023-10-14 16:43 |
SM ISO690:2012 LUNGU, Lidia, BLAJA, Svetlana, CIOCARLAN, Alexandru, ILKER, Ozer, ARICU, Aculina, VORNICU, Nicoleta. Synthesis of new active nitrogen and sulfur containing norlabdanic compounds. In: Achievements and perspectives of modern chemistry, 9-11 octombrie 2019, Chişinău. Chisinau, Republic of Moldova: Tipografia Academiei de Ştiinţe a Moldovei, 2019, p. 226. ISBN 978-9975-62-428-2. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Achievements and perspectives of modern chemistry 2019 | ||||||
Conferința "International Conference "Achievements and perspectives of modern chemistry"" Chişinău, Moldova, 9-11 octombrie 2019 | ||||||
|
||||||
Pag. 226-226 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The synthesis of hybrid terpeno-heterocyclic compounds is a recent concern of researchers in the field of natural products. Several papers describing the synthesis and biological activity of terpenic compounds bearing diazine [1,2], carbazole [2], triazole [2,3], oxadiazoleand thiadiazole [4] units have been recently published. It should be noted that the intermediates of terpenoheterocyclic compounds often exhibit biological activity. This communication confirms this fact and presents last-minute results. We report the synthesis of new di- and trinorlabdane thiosemicarbazides 1 and 2, tetranorlabdane 2-iminothiodiazole 3 and diacyl hydrazide 4, obtained in 60%-82% yields Figure 1. The structures of compounds 1-4 were fully confirmed by 1H, 13C and 2D NMR analysis.formulaFigure. New nitrogen and sulfur containing bioactive norlabdanes. Compounds 1-4 were tested in vitro for antifungal and antibacterial activity on five strains of fungi and both Gram-negative and Gram-pozitive bacteria (Table 1). Compound 3 have shown the best antifungal and antibacterial activity at (MIC) of 0.125 μg/mL and 2.5 μg/mL, respectively. Compounds 1, 2 and 4 possess activity comparable with reference compounds Caspofungin and Kanamycin (4 μg/mL). Table. Results of in vitro testing of antibacterial and antifungal activity of compounds 1-4.tabel |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-87374</cfResPublId> <cfResPublDate>2019</cfResPublDate> <cfStartPage>226</cfStartPage> <cfISBN>978-9975-62-428-2</cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/87374</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Synthesis of new active nitrogen and sulfur containing norlabdanic compounds</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p>The synthesis of hybrid terpeno-heterocyclic compounds is a recent concern of researchers in the field of natural products. Several papers describing the synthesis and biological activity of terpenic compounds bearing diazine [1,2], carbazole [2], triazole [2,3], oxadiazoleand thiadiazole [4] units have been recently published. It should be noted that the intermediates of terpenoheterocyclic compounds often exhibit biological activity. This communication confirms this fact and presents last-minute results. We report the synthesis of new di- and trinorlabdane thiosemicarbazides 1 and 2, tetranorlabdane 2-iminothiodiazole 3 and diacyl hydrazide 4, obtained in 60%-82% yields Figure 1. The structures of compounds 1-4 were fully confirmed by 1H, 13C and 2D NMR analysis.</p><p>formula</p><p>Figure. New nitrogen and sulfur containing bioactive norlabdanes. Compounds 1-4 were tested in vitro for antifungal and antibacterial activity on five strains of fungi and both Gram-negative and Gram-pozitive bacteria (Table 1). Compound 3 have shown the best antifungal and antibacterial activity at (MIC) of 0.125 μg/mL and 2.5 μg/mL, respectively. Compounds 1, 2 and 4 possess activity comparable with reference compounds Caspofungin and Kanamycin (4 μg/mL). Table. Results of in vitro testing of antibacterial and antifungal activity of compounds 1-4.</p><p>tabel</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-23821</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-52201</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-12404</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-58399</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11130</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-49779</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-23821</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-23821-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Lungu</cfFamilyNames> <cfFirstNames>Lidia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-52201</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-52201-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Blaja</cfFamilyNames> <cfFirstNames>Svetlana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-12404</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-12404-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Ciocarlan</cfFamilyNames> <cfFirstNames>Alexandru</cfFirstNames> <cfFamilyNames>Чекырлан</cfFamilyNames> <cfFirstNames>А.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-58399</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-58399-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Ilker</cfFamilyNames> <cfFirstNames>Ozer</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11130</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11130-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Aricu</cfFamilyNames> <cfFirstNames>Aculina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-49779</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-49779-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Vornicu</cfFamilyNames> <cfFirstNames>Nicoleta</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>